Abstracts tagged "autoimmunity and interferons"

Abstract Number: 832 • 2017 ACR/ARHP Annual Meeting
Single Cell Analysis Reveals Heterogeneity of Type I IFN Gene Expression in Developing Autoreactive B Cells
Jennie Hamilton¹, PingAr Yang², Qi Wu³, Bao Luo⁴, Shanrun Liu⁵, Jun Li⁶, Mark Walter⁷, Eleanor Fish⁸, Hui-Chen Hsu³ and John D. Mountz⁹, ¹Medicine/Division of Clinical Immunology and Rhematology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Microbiology, University of Alabama at Birmingham, Birmingham, AL, ⁸University Health Network & Department of Immunology, University of Toronto, Toronto General Research Institute, Toronto, ON, Canada, ⁹University of Alabama at Birmingham, Department of Medicine, Birmingham, AL
Background/Purpose: B cell development involves passage through a formative transitional B cell stage in the spleen. In SLE, self-nucleic acid reactive B cells fail to…
Abstract Number: 1249 • 2015 ACR/ARHP Annual Meeting
Differential Expression of SLE Susceptibility Genes By Interferon-Alpha and the HLA-DRB1*03:01 Haplotype in Ex Vivo B Cells
Carolina Duarte¹, Lora Boteva², Timothy Vyse¹ and Michelle Fernando¹, ¹Division of Genetics and Molecular Medicine and Division of Immunology, Infection and Inflammatory Disease, King's College London, London, United Kingdom, ²MRC Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex genetic autoimmune disease characterized by autoantibody production and up-regulation of type 1 interferons (IFNs). The strongest genetic association…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].